Can Test Reports Be Reused for Overseas Registration of Medical Dressings?

Yes, test reports can be reused for overseas registration of medical dressings, but only after verifying the target country’s regulatory requirements, product classification, report validity, and testing standard alignment. Companies should first determine whether the product qualifies as a medical device in the target market, then identify the registration pathway and applicant responsibilities based on risk class. Reports generated under NMPA, CE, FDA, or ISO 13485 systems can serve as core technical documents, but each report must be checked item by item for test standards, sample information, laboratory qualifications, and expiration dates.

Published: August 30, 2026 14:34 | Updated: August 30, 2026 14:34

Key Summary

The reusability of test reports for overseas registration of medical dressings depends on the target country’s regulatory requirements, product classification, report timeliness, and differences in testing standards. A company should first assess whether the product is a medical device under the target country’s definition, then determine the registration pathway and applicant based on risk class. Reports from NMPA, CE, FDA, or ISO 13485 can be used as core technical documents, but each must be compared item by item for test standards, sample information, laboratory qualifications, and report validity period.

Most GHWP member states and markets in Southeast Asia, the Middle East, and Latin America accept test data based on ISO or EN standards, but they require a local agent to provide an authorization letter and require localization of labels and instructions for use. Common risks include outdated report versions, inconsistent test standards, missing non-clinical studies, and insufficient biocompatibility evaluation. Companies are advised to build a master technical file library, perform gap analyses against target market requirements, and supplement toxicology, stability, or clinical evaluation data when necessary. Also pay attention to certificate control, change notification, and post-market update obligations to avoid registration certificate invalidation due to agent changes or product modifications.

For Chinese medical device companies, the most prudent approach is to first conduct product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Target market registration usually affects technical files, authorized representatives, importer collaboration, label language, quality system evidence, and subsequent change maintenance. If a project is driven only by “which documents to submit,” the company is likely to encounter correction requests or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI advises companies to plan this issue within a multi-country access strategy for GHWP member states, using one reusable core technical file to support local adaptation across different markets, rather than rebuilding documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for “can test reports be reused for overseas registration of medical dressings” usually want to know not just the concept, but whether existing documentation can support an application, whether a local agent or authorized representative is required, why the timeline is extended, and which issues will affect the launch plan. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company intends to enter multiple GHWP member states or Southeast Asian, Middle Eastern, and Latin American markets simultaneously, answering the process for a single country is insufficient. A more valuable approach is to first create reusable versions of core technical files, quality system evidence, performance verification, clinical evidence, and labeling, then localize them according to each country’s regulatory requirements.

Registration Decision Logic

The first step is to determine whether the product falls under the target country’s medical device regulatory scope. For GHWP member states such as those in ASEAN, the Middle East, and Latin America, classification is generally based on the product’s intended use and mechanism of action, not solely on Chinese classification documents.

The second step is to determine the risk class and registration route. Different risk classes require different technical documentation. Class I products typically require a declaration of conformity and basic test reports, while Class II and III products need more comprehensive performance verification, biocompatibility evaluation, clinical evaluation, or usability evidence.

The third step is to evaluate the reusability of existing documentation. The applicant must compare the test reports obtained under NMPA, CE, FDA, ISO 13485, or MDSAP certification item by item against the target country’s technical file requirements.

The fourth step is to confirm local agent and authorized representative requirements. Most overseas registrations require a local agent who holds the certificate and assumes post-market obligations. The technical content of registration test reports can be reused, but administrative documents and label/IFU must be localized.

Registration decision logic must also consider actual product changes. If the product material, structure, sterilization method, or manufacturing process changes, the original test report may no longer be valid.

Materials and Evidence

Reusable materials include test reports for physical and mechanical properties, chemical properties, microbiological indicators, sterilization validation, packaging integrity, and biocompatibility. If these reports are issued in accordance with international standards such as ISO, EN, ASTM, or USP, and the testing organization holds relevant qualifications, they can be accepted by most target country regulators.

Key information that must be checked includes sample name, model/specification, batch number, production date, test standard, conclusion, issue date, and report validity period. Some countries require that the report be issued within one or two years; otherwise, retesting is required.

If the product already has an NMPA registration certificate in China, the corresponding test reports can be used as reference documents, but NMPA registration is not a sufficient condition for overseas registration. Performance data and risk management documents in CE technical files have high reuse value, but note whether classification and general specifications under the CE mark are consistent with the target country.

For FDA, if a 510(k) or De Novo authorization has been obtained, the related non-clinical study data and substantial equivalence conclusions can support safety arguments in overseas registrations.

Biocompatibility evaluation is a frequent correction item in overseas registration of medical dressings. Most countries accept test reports under ISO 10993 series standards, but if the product contacts open wounds or is for long-term contact, chronic toxicity, genotoxicity, implantation, or degradation studies may be required.

Labels, instructions for use (IFU), shelf life, and stability reports generally need to be prepared in the target country’s language and regulatory format; Chinese versions cannot be used directly.

Common Errors

The most common mistake is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Directly translating NMPA documentation and submitting it without rearranging evidence according to the target market’s registration pathway.
• Including too many model variations without adequate test reports, clinical evidence, or labeling coverage.
• Choosing a local agent solely for sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistency among labels, IFUs, promotional materials, and registration documents, leading to correction requests or post-market compliance issues.
• Failing to plan for multi-country document reuse, resulting in duplicated effort, higher costs, and longer timelines.

Enterprise Preparation Checklist

• Determine whether the product is a medical device in each target country and classify it appropriately.
• Build a master technical file library covering preclinical studies, test reports, risk management, and production validation.
• Perform a gap analysis for each target market, listing which documents are reusable and which need supplementation.
• Confirm whether the issuing laboratory holds ISO/IEC 17025 accreditation or other recognized qualifications.
• Check report validity periods and plan for retesting or supplementary studies.
• Complete localization translation and regulatory review of labels, IFUs, and packaging.
• Appoint local agents with clearly defined responsibilities, sign authorization agreements, and retain control over certificates.
• Establish post-market surveillance and change management processes to prevent registration file invalidation due to product improvements.

AIMEILI Perspective

The easiest misconception in overseas registration of medical dressings is that “test reports are universal.” In fact, the reusability of a test report depends on the standard it was tested to, the report date, and product consistency—not all regulators accept the same report. Early in a project, the regulatory, R&D, and quality departments should work together to review the target country’s officially published registration guides and classification lists before deciding whether additional testing is needed.

We recommend building a master technical file library first, organizing existing NMPA, CE, FDA, and other reports by standard, model, and test item. Physical and chemical performance reports are often reusable in most countries, while biocompatibility, clinical evaluation, and stability reports may need supplementation.

Local agents and authorized representatives are not merely administrative roles; they communicate with regulators, receive certificates, submit change applications, and complete renewals. Companies should define certificate control and change response mechanisms in contracts to prevent agent relationship changes from affecting registration status.

For multi-country registrations, a unified master technical file with targeted country-specific gap analyses can significantly reduce duplicate documentation work and correction requests. Prepare materials using consistent test standards and report structures across markets.

Common Follow-up Questions

Do test reports have a validity period?

Physical and chemical performance reports typically do not have a strict expiration date, but regulators may require that the report be issued within a certain number of years, commonly one or two years. Biocompatibility reports are generally considered valid as long as long-term stability data supports them; if materials or processes change, re-evaluation is necessary.

Can CE reports be used directly for Southeast Asian registration?

CE reports can serve as important reference documents, but Southeast Asian countries may require additional explanations of local standards differences, supplemental biocompatibility testing, or clinical literature. Local language labels and instructions for use must be prepared, and a local authorized representative must be appointed.

Can the same medical dressing use one set of documents for multiple country registrations?

Yes, applications can be combined based on a core technical file library, but localization is required for each country. Where applicable, GHWP harmonized guidelines and joint review frameworks can reduce duplicate work, but certificate holding and post-market maintenance are still separate.

Quality System and Evidence Consistency

From a regulatory review perspective, quality system documentation is not an isolated certificate. Regulators typically check consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical documentation. If the ISO 13485 certificate scope does not match the submitted product, or if the production address, model specifications, or IFU version do not match the test reports, corrections may be requested even if extensive documentation has been provided.

Before submission, companies should create an evidence consistency checklist that maps product name, model/specification, intended use, applicable standards, test report number, clinical evaluation conclusion, risk management version, label/IFU version, and quality system certificate. This simple step can significantly reduce correction probability, especially for projects involving multiple GHWP member states or multiple product series.

Localization Conversion and Agent Responsibilities

Target market registration often involves local agents, authorized representatives, importers, or registration holders. Companies need to clarify whether the local partner is responsible only for submission or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and long-term market stability.

Labels, IFUs, and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warning statements, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into the target country’s accepted submission structure, rather than creating a completely new set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies must maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest heavily in the registration phase but neglect post-market maintenance. Later, when production address changes, model expansions, label updates, or agent replacements occur, the certificate may fall out of sync with market sales.

AIMEILI recommends integrating this issue into annual international registration planning: first define target market priorities, then build a reusable documentation package and country-specific gap list, and finally schedule submission, correction, post-market maintenance, and renewal milestones. This approach not only improves efficiency in individual country registrations but also helps companies build replicable overseas compliance capabilities and reduce the cost of starting from zero each time they enter a new market.

Related Reading

• Can test reports be reused for overseas registration of medical devices?
• How to choose a local agent for overseas registration of implantable products?
• How are responsibilities divided for authorized representatives of implantable products overseas?
• How are responsibilities divided for authorized representatives of laboratory equipment overseas?
• How to perform post-market surveillance for laboratory equipment overseas?
• When should change applications be submitted for overseas registration of disinfection and sterilization equipment?

Content Review and Applicability Boundary

Content Author: AIMEILI Regulatory Editorial Team. Professional Review: AIMEILI Medical Device International Registration Project Group. Sources: Priority is given to official regulatory bodies, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only for auxiliary judgment.

Applicability: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace formal requirements from target country regulators, test conclusions, or legal advice.